Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06433219 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Primary completion date changed from estimate of Jun 14, 2026 to Aug 11, 2026v11 Show 1 more changeShow less
    • Primary completion date changed from estimate of Jun 14, 2026 to Aug 11, 2026
  2. Primary completion pushed from Sep 29, 2025 to Jun 14, 2026 Completion date: Jun 26, 2026 to Jun 14, 2026v10 Show 1 more changeShow less
    • Completion date: Jun 26, 2026 to Jun 14, 2026
  3. Primary completion date changed from estimate of Jan 10, 2028 to Sep 29, 2025 Completion date: Jan 25, 2028 to Jun 26, 2026v9 Show 1 more changeShow less
    • Completion date: Jan 25, 2028 to Jun 26, 2026
  4. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 130 to confirmed 63 · Study sites: 58 to 84v8 Show 2 more changesShow less
    • Enrollment target: estimated 130 to confirmed 63
    • Study sites: 58 to 84
  5. Re-verified, no change to tracked fieldsv7
Show 5 earlier versionsHide 5 earlier versions
  1. Enrollment target: 60 to 130 Primary endpoints revised (2) · Eligibility criteria expanded, about 71 words · Secondary endpoints: 2 to 3 · 1 morev6 Show 4 more changesShow less
    • Primary endpoints revised (2)
    • Eligibility criteria expanded, about 71 words
    • Secondary endpoints: 2 to 3
    • Study arms: 2 to 5

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 40 to 58v5
  3. Study sites: 22 to 40v4
  4. Study sites: 1 to 22 Start date changed from estimate of Aug 5, 2024 to Oct 30, 2024v3 Show 1 more changeShow less
    • Start date changed from estimate of Aug 5, 2024 to Oct 30, 2024
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 2 to 1 · Start date: Jul 26, 2024 to Aug 5, 2024 · Eligibility criteria expanded, about 6 wordsv2 Show 3 more changesShow less
    • Study sites: 2 to 1
    • Start date: Jul 26, 2024 to Aug 5, 2024
    • Eligibility criteria expanded, about 6 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck KGaA
43 trials monitored
See 4 trials at risk
Ovarian Cancer
1,245 trials monitored
See 80 trials at risk
The purpose of this study is to measure the effect and safety of treatment with tuvusertib combined with either niraparib or lartesertib in participants with epithelial ovarian cancer and to assess any differences between tuvusertib monotherapy and combination therapy. The participants will previously have progressed while treated with a poly ADP ribose polymerase (PARP) inhibitor. The primary objectives of this study are to assess the effect of the treatment in terms of overall response, i.e. whether the tumor disappears, shrinks, remains unchanged, or gets worse and safety in terms of adverse events.
Trial Details
NCT Number NCT06433219
Lead Sponsor EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Ovarian Cancer
Enrollment 63 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov